Over the last decade, studies suggested that dietary behavior modification, including fasting,
can improve metabolic and cardiovascular markers as well as body composition. Given the …

Simple Summary When we ingest a meal, our intestine secretes hormones that are released
into the bloodstream. Amongst these hormones are the incretins hormones which stimulate …

Background Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment
of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first
introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and …

Several randomized controlled trials have demonstrated the benefits of glucagon-like
peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this …

This is a phase 1, open-label, single-sequence, multiple-dose, single-center trial conducted
in the US (NCT03790839), to evaluate the clinical pharmacokinetics, safety and …

Diabetes is a chronic disease that affects a vast number of individuals globally, and without
optimal treatment, can lead to significant health complications. Moreover, obesity is another …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat patients
with type 2 diabetes since 2005 and have become popular because of the efficacy and …

Diabetes is a serious metabolic disease in which chronic hyperglycemia results in diabetic
microvascular and macrovascular complications from progressive vascular damage and …

Background & Aims Concerns have been raised that the incretin-based diabetes drugs
dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor …